Lookup NU author(s): Professor Tiago Outeiro
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Metabolites of the kynurenine pathway (KP), which arise from the degradation of tryptophan, have been studied in detail for over a century and garnered the interest of the neuroscience community in the late 1970s and early 1980s with work uncovering the neuromodulatory potential of this pathway. Much research in the following decades has found that perturbations in the levels of KP metabolites likely contribute to the pathogenesis of several neurodegenerative diseases. More recently, it has become apparent that targeting KP enzymes, in particular kynurenine 3-monooxygenase (KMO), may hold substantial therapeutic potential for these disorders. Here we provide an overview of the KP, the neuroactive properties of KP metabolites and their role in neurodegeneration. We also discuss KMO as a therapeutic target for these disorders, and our recent resolution of the crystallographic structure of KMO, which will permit the development of new and improved KMO inhibitors which may ultimately expedite clinical application of these compounds. © 2013 Springer-Verlag Berlin Heidelberg.
Author(s): Amaral M, Outeiro TF, Scrutton NS, Giorgini F
Publication type: Review
Publication status: Published
Journal: Journal of Molecular Medicine
Print publication date: 01/06/2013
Online publication date: 01/05/2013
ISSN (print): 0946-2716
ISSN (electronic): 1432-1440
PubMed id: 23636512